Beryl Drugs

Beryl_Drugs02 May 2024

Pharmaceuticals

₹

+0.14 (+0.40%)

Lowest Today

Highest Today

Prev. Close

Today’s Open

52 Week High

52 Week Low

BUY

SELL

To Invest in Beryl Drugs

Beryl Drugs

Pharmaceuticals

Beryl_Drugs02 May 2024

₹

+0.14 (+0.40%)

OverviewFundamentals

Corporate action

Peer comparison

Income Sheet

Balance sheet

Cash flow

Share holding

About Us

Corporate Action

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

All

Dividends

Bonus

Splits

Others

Ex-Date	Type	Description	Record Date
12-Apr-2024	BC	BERYL DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/04/2024 inter alia to consider and approve 1. To take note of general disclosures of	20-Apr-2024
01-Feb-2024	BC	BERYL DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2024 inter alia to consider and approve the Unaudited Financial Result of the Company	12-Feb-2024
31-Oct-2023	BC	BERYL DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2023 inter alia to consider and approve TO CONSIDER AND APPROVE THE UNAUDITED FINANCIA	08-Nov-2023
25-Aug-2023	BC	AGM 21/09/2023 Notice of 30th Annual General Meeting held on 21st Day of September, 2023 at 10:00 BOOK CLOSURE FOR THE PURPOSE OF ANNUAL GENERAL MEETING OF THE COMPANY FROM 15TH SEPTEMBER, 2023	21-Sep-2023
21-Sep-2023	BC	PROCEEDINGS OF 30TH ANNUAL GENERAL MEETING	21-Sep-2023

No Rights has been declared by Beryl_Drugs

Book Closure

Record Date	Split Date	Purpose
20-Apr-2024	-	BERYL DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/04/2024 inter alia to consider and approve 1. To take note of general disclosures of
12-Feb-2024	-	BERYL DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2024 inter alia to consider and approve the Unaudited Financial Result of the Company
08-Nov-2023	-	BERYL DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2023 inter alia to consider and approve TO CONSIDER AND APPROVE THE UNAUDITED FINANCIA
21-Sep-2023	-	AGM 21/09/2023 Notice of 30th Annual General Meeting held on 21st Day of September, 2023 at 10:00 BOOK CLOSURE FOR THE PURPOSE OF ANNUAL GENERAL MEETING OF THE COMPANY FROM 15TH SEPTEMBER, 2023
21-Sep-2023	-	PROCEEDINGS OF 30TH ANNUAL GENERAL MEETING

Peer Comparison

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Scrip Name	Price	Daily Change	M.Cap (Cr)	1 Year Returns %	P/E (TTM)	PB Ratio
Beryl Drugs Ltd ₹35.38(+0.14/0.40%)	35.38	+0.14	17.87	163.97	15.19	1.99
Astrazeneca Pharma India Ltd ₹5,327.45(-13.80/-0.26%)	5,327.45	-13.80	13,353.13	68.03	83.72	20.39
Bliss GVS Pharma Ltd ₹128.40(+4.70/3.80%)	128.40	+4.70	1,295.03	60.30	18.97	1.32
Cipla Ltd ₹1,417.00(+15.80/1.13%)	1,417.00	+15.80	113,132.18	52.94	34.40	4.37
Abbott India Ltd ₹26,686.25(+270.50/1.02%)	26,686.25	+270.50	56,133.47	18.05	49.00	18.06
Amrutanjan Health Care Ltd ₹741.55(+43.60/6.25%)	741.55	+43.60	2,017.82	15.18	45.86	7.70

Income Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	7.62	8.03	8.11	6.11	8.15	7.69
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	7.62	8.03	8.11	6.11	8.15	7.69
Other Operating Income	0.04	0.06	0.07	-0.02	0.04	0.21
Other Income	0.00	0.00	0.00	0.00	0.00	0.00
Total Income	7.66	8.09	8.17	6.09	8.19	7.90
Total Expenditure	6.86	7.37	7.04	5.82	7.48	7.27
PBIDT	0.80	0.72	1.13	0.27	0.72	0.63
Interest	0.11	0.10	0.12	0.06	0.12	0.11
PBDT	0.68	0.62	1.01	0.21	0.60	0.52
Depreciation	0.31	0.29	0.28	0.15	0.22	0.19
Tax	0.11	0.16	0.24	0.01	0.00	0.00
Deferred Tax	-0.05	-0.10	-0.04	-0.02	0.23	-0.02
Reported Profit After Tax	0.31	0.27	0.53	0.06	0.14	0.34
Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	0.31	0.27	0.53	0.06	0.14	0.34

EPS (Unit Curr.)	0.61	0.54	1.05	0.12	0.28	0.67
EPS (Adj) (Unit Curr.)	0.61	0.54	1.05	0.12	0.28	0.67
Calculated EPS (Unit Curr.)	0.61	0.54	1.05	0.12	0.28	0.67
Calculated EPS (Adj) (Unit Curr.)	0.61	0.54	1.05	0.12	0.28	0.67
Calculated EPS (Ann.) (Unit Curr.)	2.45	2.16	4.18	0.50	1.13	2.70
Calculated EPS (Adj) (Ann.) (Unit Curr.)	2.45	2.16	4.18	0.50	1.13	2.70
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	5.07	5.07	5.07	5.07	5.07	5.07
Reserve & Surplus	0.00	0.00	0.00	0.00	0.00	0.00
Face Value	10.00	10.00	10.00	10.00	10.00	10.00

Public Shareholding (No. Of Shares)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (% in Equity)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	10.50	8.97	13.93	4.42	8.83	8.19
PBDTM(%)	8.92	7.72	12.45	3.44	7.36	6.76
PATM(%)	4.07	3.36	6.54	0.98	1.72	4.42

Balance Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	5.09	5.09	5.09	5.09	5.09	5.09
Reserves Total	2.97	2.20	2.84	2.53	2.43	1.57
Equity Share Warrants	0.00	0.00	0.00	0.00	0.00	0.00
Equity Application Money	0.00	0.00	0.00	0.00	0.00	0.00
Total Shareholders Funds	8.06	7.29	7.93	7.62	7.52	6.66
Secured Loans	4.54	1.92	2.77	2.84	1.49	0.09
Unsecured Loans	0.00	3.37	2.35	2.39	1.76	1.39
Total Debt	4.54	5.29	5.12	5.23	3.25	1.48
Total Liabilities	12.60	12.58	13.05	12.85	10.77	8.14
APPLICATION OF FUNDS :
Gross Block	10.86	10.06	10.46	10.26	2.96	2.92
Less : Accumulated Depreciation	4.83	4.02	2.93	1.66	1.00	0.70
Less:Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	6.03	6.04	7.53	8.60	1.96	2.22
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	0.00	0.00	0.00	0.00	6.24	0.08
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	0.15	0.16	0.12	0.56	0.48	0.22
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	1.05	2.98	2.27	1.16	0.76	1.35
Sundry Debtors	6.90	4.45	4.54	3.45	3.44	4.83
Cash and Bank	0.57	0.27	0.45	0.40	0.10	0.14
Loans and Advances	1.79	2.93	2.89	2.51	1.10	0.70
Total Current Assets	10.32	10.63	10.15	7.52	5.40	7.02
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	4.41	4.77	5.01	3.68	3.57	2.49
Provisions	0.10	0.10	0.07	0.03	0.01	0.01
Total Current Liabilities	4.51	4.88	5.08	3.71	3.59	2.50
Net Current Assets	5.81	5.75	5.07	3.81	1.81	4.51
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	0.41	0.36	0.14	0.14	0.08	0.00
Deferred Tax Liability	0.28	0.27	0.34	0.22	0.00	0.00
Net Deferred Tax	0.13	0.09	-0.20	-0.08	0.08	0.00
Total Assets	12.12	12.04	12.51	12.89	10.57	7.02
Contingent Liabilities	2.03	1.21	1.21	0.44	1.09	1.35

Cash Flow

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

PARTICULARS	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019
Cash and Cash Equivalents at Beginning of the year	0.27	0.45	0.40	0.10	0.14
Net Cash from Operating Activities	2.48	-0.29	0.34	0.18	3.35
Net Cash Used In Investing Activities	-1.30	0.54	0.26	-1.55	-5.01
Net Cash Used In Financing Activities	-1.17	-0.43	-0.54	1.67	1.62
Net Inc./Dec In Cash And Cash Equivalents	0.01	-0.18	0.06	0.30	-0.04
Cash And Cash Equivalents At End Of The Year	0.28	0.27	0.45	0.40	0.10

Share Holding

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Promoter Shareholding

26.38%

FII Shareholding

0.00%

DII Shareholding

0.00%

Public Shareholding

73.62%

**Promoter pledged shareholding 26.38%

About Beryl Drugs Ltd

Beryl Drugs Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 17.87 crores. It has reported a sales of Rs. 7.62 crores and a net profit of Rs. 0.31 crores for the quarter ended December 2018. The company management includes Sudhir Sethi, Sanjay Sethi,Sudhir Sethi,Abhinav Naik,Shreya Saraf (Beryl Drugs Ltd) among others.

Chairman

Sudhir Sethi

Registered office

133 Kanchan Bag,,Indore,Madhya Pradesh,452001

FAX :91-731-25065375/3046366

Background

Incorporation Year1993

Face Value₹10

Market Lot1

How to buy Beryl Drugs shares on nse?

To buy Beryl Drugs shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the Beryl Drugs share price today?

The Beryl Drugs shares price on nse is Rs.35.38 today.

What is the market cap of Beryl Drugs shares on BSE ?

The company has a market capitalization of Rs.17.87Cr

What is the PE & PB ratio of Beryl Drugs shares ?

PE is 15.19 and PB is 1.99

What is the 52 Week High and Low of Beryl Drugs shares?

Beryl Drugs stock price high: Rs.44.98 Beryl Drugs stock price low: Rs.13.1